Bioretec (OHEL:BRETEC) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


What is Bioretec Research & Development?

Bioretec OHEL:BRETEC +7.48% Research & Development is €0.00 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bioretec's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Bioretec  (OHEL:BRETEC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bioretec Research & Development Related Terms

Bioretec Research & Development Historical Data

* Premium members only.

The historical data trend for Bioretec's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioretec Research & Development Chart

Bioretec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Bioretec Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioretec Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Bioretec (OHEL:BRETEC) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Bioretec and its competitors.
Is Bioretec's Research & Development too high?
Bioretec's current Research & Development is €0.00 Mil.
How does Bioretec's Research & Development compare to ABT and SYK?
Bioretec's Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bioretec and its competitors. Bioretec's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioretec stock overvalued right now?
Based on GuruFocus' analysis, Bioretec (OHEL:BRETEC) is currently considered Possible Value Trap. The stock's GF Value™ is €0.19, compared to a current price of €0.02 — trading 87.9% below its estimated fair value. The current Research & Development is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bioretec (OHEL:BRETEC), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioretec Business Description

Other Exchanges 0TN:Germany
Address Yrittajankulma 5, Tampere, FIN, 33710
Bioretec Ltd is a medical device company focusing on the development of bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. It has developed the following product lines: RemeOs and Activa. RemeOs is based on a high-performance magnesium alloy and hybrid composite, introducing absorbable materials for enhanced surgical outcomes. The RemeOs implants (RemeOs Screw Lag, RemeOs Screw Lag Solid, RemeOs Screw FT, etc.) are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The Activa implants (ActivaPin, ActivaNail, ActivaScrew, etc.) are based on fully absorbable biopolymer products that facilitate natural bone healing without requiring removal surgery.